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Background
•

•

Objectives

Lung adenocarcinoma (LUAD) represents the most
common subtype of lung cancer1. Patients with KRASmutant LUADs (KM-LUADs) common to smokers
display dismal clinical outcomes and resistance to
targeted therapies3.
Our group recently identified alveolar intermediary cells
(AICs) that arise early on post-tobacco carcinogen
exposure in vivo and during AT2-mediated repair
mechanisms. Notably, and prior to tumor onset, a
subset of AICs harbored driver KrasG12D mutations
which were later found in the resultant LUADs, and
which comprise the same variants found in human
smokers with KM-LUADs. These findings support a role
for AICs as precursors for KM-LUAD pathogenesis (Fig
1a). Our ongoing studies are studying AICs at high
resolution to identify targets for early prevention and/or
interception of KM-LUAD pathogenesis, including
specifically targeting KrasG12D mutation (Fig 1b).

•

Confirm the ability of MRTX 1133 to specifically downregulate downstream products of KrasG12D in a murine LUAD
cell line (mF471).

•

Study the pharmacokinetics of murine KrasG12D inhibition by MRTX 1133 to determine the onset of action and
minimal inhibitory concentration (MIC).

Methods
•

MTT Proliferation Assay: mF471 cells were plated on day 1, treated with MRTX 1133 (0nM, 1 nM, 10 nM, and
100nM) and Epidermal Growth Factor (50 ng/mL) on day 2, and MTT proliferation assay measured on day 4 (Fig 3a).
Each well contains 1000 cells.

•

Western Blot: mF471 cells were plated on day 1, treated with MRTX 1133 (0 nM, 1nM, 10nM, and 100nM) and
Epidermal Growth Factor (50 ng/mL) on day 3 for 1 and 3 hours before analysis (Fig 3b). 200 ug protein was loaded
per lane.

Results
A

B

A

Figure 3. (a) MTT Proliferation Assay of mF471 cells treated with MRTX1133. * P <0.05, ** P <0.01, *** P <0.001.
(b) Immunoblot protein western analyses of mF471 cells treated with (C) media alone for control; (E) 50 ng/mL
EGF; (1) 50 ng/mL EGF + 1nM MRTX1133; (10) 50 ng/mL EGF + 10 nM MRTX1133; (100) 50 ng/ mL EGF + 100
nM MRTX 1133.

B
Figure 1. (a) Trajectory analysis of
KACs and malignant cells implicated in
human KM-LUAD development.
Adapted from Han G (2022).
(b) Fraction of KrasG12D mutant cells
(right) in KACs, malignant, AT1 and AT2
subsets. Absolute numbers of
KrasG12D mutant cells are indicated on
top of each bar. Figure and legend
adapted from Han G, Sinjab A (2022).

Conclusions & Future Directions
•

Increasing concentrations of MRTX 1133 result in statistically significant decreases in cell viability when compared to
control.

•

MRTX1133 shows dose-dependent inhibition of Kras signaling at all time points tested. A significant reduction in key
KRAS pathway signaling molecules were observed as early as 3 hours and with concentration as little as 1 nM.
These results suggest that MRTX 1133 is a potent KrasG12D inhibitor which has the potential to inhibit murine Kras
mutant lung cancer cell lines.

•
•

•

Mutated KRAS has been an elusive target prior to the
discovery of a conserved switch II binding pocket
among all KRAS proteins. A structure-based drug
design identified MRTX 1133 as a potent and selective
KRASG12D inhibitor in both in vitro and in vivo models
(Fig 2)2. While previous testing utilized patient-derived
xenograft tumor models and orthotopic pancreatic
cancer models2, we investigate the effectiveness of
MRTX 1133 in murine lung cancer cells as a precursor
to potential clinical prevention of KM-LUAD in vivo.

Figure 2. Crystal structure of
KRASG12D bound to MRTX
1133 via the switch II binding
pocket. Figure adapted from
Christensen J (2022).

Further experiments are warranted to assess the role of inhibiting KrasG12D during the early stages of LUAD
pathogenesis in an in vivo model (Figure 4). Our group previously showed that mice with knockout of Gprc5a (Gprc5a-/-)
develop pre-malignant lesions (PMLs) and LUADs which were markedly accelerated with exposure to nicotine-specific
nitrosamine ketone (NNK), a tobacco carcinogen that is casually linked to lung cancer in humans. Hence, we will
investigate the anti-tumor effects (including preventive) of MRTX 1133 in a mouse model of tobacco-associated KMLUAD (Gprc5a-/-) and in 3D organoid models of tumor precursors from the same mice.
Figure 4. Experimental
scheme to investigate the
anti-tumor potential of MRTX
1133 in Gprc5a-/- mice. Briefly,
NNK will be given for 8 weeks.
MRTX1133 (or control) will be
administered at several
stages of LUAD pathogenesis
(AICs, PMLs, and invasive
LUAD).
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